Aug 07, 2019 4:10 pm EDT CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug 05, 2019 8:00 am EDT CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer
Jul 31, 2019 4:23 pm EDT CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7
Jun 18, 2019 8:00 am EDT CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
Jun 17, 2019 8:00 am EDT CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference
Jun 11, 2019 7:00 am EDT CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
May 20, 2019 4:01 pm EDT CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019
May 08, 2019 4:05 pm EDT CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update
Apr 30, 2019 8:00 am EDT CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8